153 results about "Extracellular fluid" patented technology

The invention is directed to a treatment of diseases that are accompanied by quantitative and / or qualitative changes of blood extracellular DNA and, more particularly, to a treatment of systemic bacterial, fungal and protozoan infections. The inventive method comprises introducing a treatment agent into a circulating blood system of a patient diagnosed with systemic infection caused by bacteria, fungi or protozoa, wherein said treatment agent destroys extracellular DNA in said blood of said patient and wherein said treatment agent used to destroy said extracellular DNA is a DNase enzyme: said agent being administered in doses and regimens which are sufficient to decrease the average molecular weight of circulating extracellular blood DNA in the blood of said patient; such decrease in the average molecular weight can be measured by gel electrophoresis of extracellular blood DNA fraction from the blood of said patient. A DNase enzyme may be applied in a dose and regimen that provide a DNase DNA hydrolytic activity measured in blood plasma that exceeds 1.5 Kunitz units per 1 ml of blood plasma for more than 12 hours within a period of 24 hours.

The invention relates to a method and device for dialysis and or bulk fluid removal by generating a fibrosis chamber within a body cavity and performing dialysis or bulk fluid removal. An implantable medical device is described having a fibrosis chamber and a pump. A dialysis chamber and an optional electrodialysis unit can further be provided. An additional controller uses sensory feedback to regulate the fluid levels by altering the extracellular fluid retention within the fibrosis chamber. This device can be used for the treatment of patients with chronic kidney disease who may also be suffering from cardiorenal syndrome and hypertension.

A flexible mounting base to hold a sensor at an infusion site, the sensor being a removable in vivo sensor for monitoring analyte concentration level in a patient, such as blood glucose (BG) level. The mounting base comprises a flexible adhesive that anchors the flexible sensor set at an infusion site to provide stability for the sensor set in a convenient and comfortable manner. Placement of the mounting base onto the patient's skin causes the insertion needle to pierce the skin for transcutaneous placement of the cannula with the sensor therein. The insertion needle can then be withdrawn to leave the cannula and sensor at the selected insertion position, with the distal segment of the sensor being exposed to patient extracellular fluid via apertures formed in the cannula.

The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically. The invention peptides have the formula:R1-Cys-Phe-Gly-Arg- Arg /  - Leu /  -Asp-Arg-                    Lys    Met                                               (1)   Ile- Gly /  -Ser- Leu /  -Ser-Gly-Leu-Gly-Cys-R-2        Ser        Serwherein R1 is selected from the group consisting of:                                             (H);                                            Gly-;                                        Ser-Gly-;                                  Asp /                                   Lys /  -Ser-Gly-;                                  Gly                           Arg /    Asp /                            His /  - Lys / -Ser-Gly-;                           Gln    Gly                           Arg /    Asp /                     Met /  - His /  - Lys /  -Ser-Gly-;                    Val    Gln    Gly                           Arg /    Asp /              Thr /  - Met /  - His /  - Lys /  -Ser-Gly-;             Met    Val    Gln    Gly                           Arg /    Asp /         Lys- Thr /  - Met /  - His /  - Lys /  -Ser-Gly-;             Met    Val    Gln    Gly                           Arg /    Asp /     Pro-Lys- Thr /  - Met /  - His /  - Lys /  -Ser-Gly-;             Met    Val    Gln    Gly                           Arg /    Asp / Ser-Pro-Lys- Thr /  - Met /  - His /  - Lys /  -Ser-Gly-;             Met    Val    Gln    Glyor a 10- to 109-amino acid sequence shown as the native upstream sequence for porcine, canine or human BNP in FIG. 8, or a composite thereof;R2 is (OH), NH2, or NR′R″ wherein R′ and R″ are independently lower alkyl (1-4C) or isAsn / LysAsn / -ValLysAsn / -Val-LeuLysAsn / -Val-Leu-ArgLysAsn / -Val-Leu-Arg- Arg / Lys                LysAsn / -Val-Leu-Arg- Arg / - Tyr / Lys                Lys    Hisor the amides (NH2 or NR′R″) thereof,with the proviso that if formula (1) isR1-Cys-Phe-Gly-Arg-Arg-Leu-Asp-Arg-   Ile-Gly-Ser-Leu-Ser-Gly-Leu-Gly-Cys-R2and R1 is Asp-Ser-Gly-, R2 cannot be Asn-Val-Leu-Arg-Arg-Tyr.The peptides of the invention can be formulated into pharmaceutical compositions and used to treat conditions associated with high extracellular fluid levels, especially congestive heart failure.

A method and apparatus for measuring changes in cell volume generally includes introducing cells into a chamber having a volume between 2 and 100 times the volume of the introduced cell. A first electrically conductive extracellular fluid is introduced into the chamber and a current is applied. The voltage induced by said current flow is measured. The first fluid is exchanged with a second electrically conductive extracellular fluid and a current is applied. The voltage induced by said current flow is measured. The first induced voltage result and the second induced voltage result are used in conjunction with known voltages induced by such current flows to monitor changes in the volume corresponding to fluid flow between the cell and an extracellular fluid.

By use of a parameter representing an intracellular / extracellular fluid ratio which is included in a parameter value associated with a bioelectric impedance measured at a given frequency or a parameter value associated with a bioelectric impedance measured at other frequency, the parameter value associated with the measured bioelectric impedance is corrected, and a body composition and the like are estimated based on the corrected parameter value associated with the bioelectric impedance. Further, the parameter to be corrected which is associated with the bioelectric impedance is the absolute value of the bioelectric impedance, a bioelectric impedance vector value or the resistance component value of the bioelectric impedance vector.

A method of determining an indication of the hydration status relating to a subject. The method includes determining a measured impedance value for at least one body segment, and then; for each body segment, using the measured impedance values to determine at least one indicator at least partially indicative of a level of extracellular fluid. Indicators can then be used to determine an indication of the hydration status.

The present invention provides a method for regulating blood pressure in a hemodialysis subject using a vasopressin receptor agonist, so as to facilitate removal of excessive extracellular fluid in the subject.